University of Michigan

Zhuo Chen

Shaomeng Wang

Ester Fernandez-Salas

Liu Liu

Donna McEachern

Chao-Yie Yang

Longchuan Bai

Bing Zhou

Fuming Xu

Jiantao Hu

Yang Hu

Chong Qin

Liyue Huang

Dengyou Zhang

Canhui Zheng

The present disclosure provides compounds represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R, R, R, R, R, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer. 

Fused 1,4-oxazepines as BET protein degraders

The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, X, W, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I and II for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer. 

Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors

Growing community of inventors

Ann Arbor, MI, United States of America

Zhuo Chen